Sugi Predict

Sugi Predict / Compounds / SCHEMBL2494570

SCHEMBL2494570

SCHEMBL2494570

Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)cn1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 7/20 0.81
▸ MAPK14 Q16539 3/20 0.81
▸ CYP2C9 P11712 2/20 0.81
▸ BRAF P15056 2/20 0.81
▸ JAK2 O60674 1/20 0.81
▸ PDGFRB P09619 1/20 0.81
▸ FGFR1 P11362 1/20 0.81
▸ EPHB4 P54760 1/20 0.81
▸ PTK2 Q05397 1/20 0.81
▸ BTK Q06187 7/20 0.79
▸ LCK P06239 7/20 0.78
▸ KDR P35968 3/20 0.78
▸ KCNQ3 O43525 2/20 0.67
▸ KCNQ2 O43526 2/20 0.67
▸ KCNE1 P15382 2/20 0.67
▸ KCNQ1 P51787 2/20 0.67
▸ KCNQ5 Q9NR82 1/20 0.67
▸ KIT P10721 2/20 0.66
▸ BLK P51451 1/20 0.62
▸ TEK Q02763 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933086 0.91 CSF1R (0.80) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL3936664 0.90 CSF1R (1.00) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL14286496 0.90 CSF1R (0.75) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL15998211 0.89 BTK (1.00) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL2944882 0.88 LCK (1.00) CSF1RMAPK14CYP2C9BRAFBTK
SCHEMBL2950273 0.87 CSF1R (0.81) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL3932964 0.87 CSF1R (0.74) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL2497726 0.86 BTK (0.83) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL3935020 0.86 CSF1R (0.75) CSF1RMAPK14CYP2C9BRAFJAK2
SCHEMBL2493840 0.85 BTK (0.79) CSF1RMAPK14CYP2C9BRAFJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 CSF1R 575/4885MAPK14 534/4885CYP2C9 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.